Govt verifying local availability of Drugs & Medical Devices

The list contains 110 drugs and medical devices for which procurement will be done by ministry of railways.

218
Govt DoP

Last Updated on September 20, 2021 by The Health Master

The Department of Pharmaceuticals (DoP) has sought feedback from pharma and medical device industry associations on local availability of drugs and medical devices for which ministry of railways seeking exemption from revised Public Procurement (Preference to Make in India) order, 2017.

The list contains 110 drugs and medical devices for which procurement will be done by ministry of railways.

Some of the drugs mentioned in the list are:

  • Abemaciclib 150 mg tablet, dulaglutide 0.75 mg injection manufactured by Eli Lilly and Company India,
  • Tocilizumab 80 mg injection (Actemra) manufactured by Cipla,
  • Afatinib 20 mg tablet and alteplase 50 mg by Boehringer Ingelheim Pharma,
  • Aflibercept injection 40 mg vial by manufactured by Bayer AG and marketed Bayer Zydus Pharma,
  • Alecensa 150 mg tablet by Excella GmbH, Germany,
  • Basiliximab 20 mg vial by Novartis Healthcare,
  • Brolucizumab injection, eltrombopag olamine 25 mg tablet by Novartis Pharmaceuticals,
  • Palbociclib 125 mg and ceftaroline 600 mg vial by Pfizer,
  • Cetuximab 100 mg by Merck Specialities Ltd,
  • Creon 10000 by Abbott Products,
  • Dapagliflozin 10 mg tablet, durvalumab 120 mg vial, goserelin 10.8 mg SR injection and by Astrazeneca Pharmaceuticals.
  • Emicizumab 30 mg/ml injection by Hoffmann LA Roche,
  • Ibrutinib 140 mg by Pharmacyclics Inc,
  • Ruxolitinib 5 mg tablet,
  • Nilotinib 150 mg tablet by Novartis Pharma,
  • Canagliflozin 100 mg tablet by Janssen
  • Cilag, liraglutide 6 mg/ml by Novo Nordik India,
  • Nivolumab 100 mg injection by Bristol Myers Squibb Holding.

Apart from them, the list contains medical devices such as:

  • Tisseel Kit 2 ml by Baxter India,
  • Insulin Deludec 100 iu/ml- 3 ml prefilled pen by Novo Nordik,
  • Hyaluronic Acid injectable implant 200 mg by Bioventus Carolina USA and
  • Monocomponent insulin Lispro 100 IU/ml – 3 ml penfills/cartridges by Eli Lilly and Company etc.

These products do not have any indigenous manufacturer having local content of more than 20 per cent.

Hence the ministry of railways appealed to DoP to exempt these items from revised Public Procurement (Preference to Make in India) Order, 2017 so that global tender can be issued for procurement of these products.

In this connection, DoP asked pharma and medical device industry associations to provide their inputs with respect to the local manufacturing capacity of each of these items and availability of local content, in case they are produced in India. Also, as to whether these are patented molecule having no generic molecule available in the country.

The DoP requested the associations to provide inputs by September 21, 2021.

Illegal Blood supply racket busted

Amoxycillin: Investigation of Anti Dumping duty

Proposed 12% GST on APIs not to benefit Bulk Drug Manufacturers

Nutraceuticals: A strong Regulation is needed

India and Pharmacy Education: Chapter: 7

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner